Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2019 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
Maher AR, Theodore G. Maher AR, et al. J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. doi: 10.18553/jmcp.2012.18.s5-b.1. J Manag Care Pharm. 2012. PMID: 22784311 Free PMC article.
Beginning in 2006, 9 atypical antipsychotic drugs have been approved by the FDA for indications that were previously off-label uses: aripiprazole (as augmentation for major depressive disorder [MDD] and for autism spectrum disorders), asenapine, clozapine, iloperidone, ola …
Beginning in 2006, 9 atypical antipsychotic drugs have been approved by the FDA for indications that were previously off-label uses: aripipr …
Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.
Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG. Maher AR, et al. JAMA. 2011 Sep 28;306(12):1359-69. doi: 10.1001/jama.2011.1360. JAMA. 2011. PMID: 21954480
Controlled trials comparing an atypical antipsychotic medication (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, asenapine, iloperidone, or paliperidone) with placebo, another atypical antipsychotic medication, or other pharmacotherapy for adult off-label …
Controlled trials comparing an atypical antipsychotic medication (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, asenapi …
Off-Label Use of Second-generation Antipsychotics in Bipolar Disorder: A Survey of Italian Psychiatrists.
Salvi V, Cerveri G, Aguglia A, Calò S, Corbo M, Martinotti G, Serafini G, Signorelli MS, Aguglia E, Amore M, Biggio G, DI Sciascio G, Mencacci C. Salvi V, et al. J Psychiatr Pract. 2019 Jul;25(4):318-327. doi: 10.1097/PRA.0000000000000405. J Psychiatr Pract. 2019. PMID: 31291215
For maintenance treatment of BD, off-label asenapine was considered appropriate by 45% of the psychiatrists, followed by long-acting aripiprazole and olanzapine pamoate, which were considered appropriate by 37.1% and 23.8%, respectively. ...
For maintenance treatment of BD, off-label asenapine was considered appropriate by 45% of the psychiatrists, followed by long-acting …
Antipsychotic treatment patterns and cardiometabolic medicine use: current real-world evidence.
Radha Krishnan RP, Zoega H, Buckley NA, Raubenheimer JE. Radha Krishnan RP, et al. Epidemiol Psychiatr Sci. 2026 Feb 11;35:e10. doi: 10.1017/S2045796026100468. Epidemiol Psychiatr Sci. 2026. PMID: 41669909 Free PMC article.
However, the prevalence of cardiometabolic medicine use for continuous ( 1 year) low-dose use of aripiprazole, asenapine, brexpiprazole, chlorpromazine, lurasidone, olanzapine, periciazine and quetiapine was also elevated (13-43%). ...
However, the prevalence of cardiometabolic medicine use for continuous ( 1 year) low-dose use of aripiprazole, asenapine, brexpiprazo …